32nd week of 2010 patent applcation highlights part 38 |
Patent application number | Title | Published |
20100203104 | DELIVERY SYSTEM FOR RISPERIDONE - This invention relates to an extended release formulation comprising solid risperidone, which formulation is a vaginal device having a skin and which device comprises an inner compartment made of a thermoplastic polymer, which polymer is containing risperidone. The polymer is preferably made of ethylene-vinyl acetate copolymer. | 2010-08-12 |
20100203105 | METHOD FOR ADMINISTERING INSULIN TO THE BUCCAL REGION - A mixed micellar pharmaceutical formulation includes a micellar pharmaceutical agent, an alkali metal C8 to C22 alkyl sulfate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compound. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening primrose oil, trihydroxy oxo cholanyiglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. Each absorption enhancing compound is present in a concentration of from 1 to 10 wt:/wt. % of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt. % of the formulation. Methods for administering insulin and heparin to the buccal region are also disclosed. | 2010-08-12 |
20100203106 | METHOD FOR ENCAPSULATING AMINO ACIDS, VITAMINS AND MEDICATIONS AND METHOD FOR INCREASING RUMEN BYPASS OF AMINO ACIDS, VITAMINS AND MEDICATIONS - A method for encapsulating amino acids, vitamins and/or medications where the rumen bypass of the amino acids, vitamins and/or medications is increased. Ruminant supplements produced by the method for encapsulating, methods for producing milk and methods for increasing the production of milk protein. | 2010-08-12 |
20100203107 | Methods of Administering a Dermatological Agent to a Subject - Methods for administering a dermatological agent to a subject are provided. In the subject methods an effective amount of a topical formulation of the dermatological agent is topically applied to a host. The topically applied formulation of dermatological agent is then occluded with a hydrogel patch, where a feature of the hydrogel patch is that it lacks a pharmaceutically active agent. Also provided are methods of treating a subject for a disease condition by administering a dermatological agent to the subject. Also provided are kits for use in practicing the subject methods. The subject methods and compositions find use in a variety of different applications. | 2010-08-12 |
20100203108 | Patch and patch preparation - The present invention provides to a patch and a patch preparation having low stretchability, which can be continuously adhered to the skin for a long time without undesirable detachment and marked falling off from the skin due to various factors during adhesion, and specifically provides a low stretchable patch and a patch preparation containing a support and an adhesive layer formed on one surface of the support, wherein a ratio P of the total length W (mm) of curved sections of a planar outer shape of the patch to the total length S (mm) of straight-line sections of the planar outer shape of the patch (W/S) is not more than 1.22, and, when the curved sections are approximated by a circular arc, the radius R (mm) of the circular arc is not less than 0.5 mm. | 2010-08-12 |
20100203109 | Methods and Compositions for Treating Melanoma | 2010-08-12 |
20100203110 | Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production - The present invention relates to methods of treating a cancerous tumor in a subject comprising administering to the subject an effective amount of 3-bromopyruvate. The 3-bromopyruvate may be administered intraarterially directly to a tumor as a continuous intraarterial infusion. The present invention also relates to methods for identifying agents that inhibit type II hexokinase activity. | 2010-08-12 |
20100203111 | G-SUBSTRATE FOR THE TREATMENT AND PREVENTION OF PARKINSON'S DISEASE - The invention features methods and compositions for the treatment and prevention of Parkinson's Disease. | 2010-08-12 |
20100203112 | COMPOSITION OF CATIONIC PHOSPHOLIPID NANOPARTICLES FOR EFFECTIVE DELIVERY OF NUCLEIC ACIDS - The present invention provides a cationic phospholipid liposome composition comprising 1,2-dioleoyl-sn-glycero-S-ethylphosphocholine (EDOPC), 3β-[N—(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-cholesterol) and 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhPE), a liposome-nucleic acid complex which is capable of forming a complex therewith, and a pharmaceutical composition comprising the same. The cationic phospholipid liposome of the present invention is highly effective for intracellular delivery of nucleic acids and reduction of cytotoxicity, as compared to conventional liposome products. Therefore, the present invention can be useful for gene therapy via intracellular delivery of a desired material to target cells. | 2010-08-12 |
20100203113 | WNT SIGNALLING INHIBITORS, AND METHODS FOR MAKING AND USING THEM - The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e.g., in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell. | 2010-08-12 |
20100203114 | MICELLE ENCAPSULATION OF THERAPEUTIC AGENTS - The invention provides 17 AAG encapsulated in micelle particles. The micelles can be comprised of safe poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA). A significant advantage of PEG-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO. Additionally, PEG-PLA micelles are easier to handle than DMSO and they do not possess foul odors, which is a problem associated with 17-AAG formulations currently in clinical trials. The invention also provides methods of preparing active agents encapsulated micelles and therapeutic methods of using the micelles and their corresponding formulations, such as for the inhibition of Hsp 90, and/or for the treatment of cancer. | 2010-08-12 |
20100203115 | ORGANIC-INORGANIC HYBRID MATERIAL FOR THE STORAGE AND RELEASE OF ACTIVE PRINCIPLES - This invention relates to a hybrid material composed of organic-inorganic particles, characterised in that said particles have a diameter of between 10 and 800 nm, and it is structured in two portions:
| 2010-08-12 |
20100203116 | USE OF LIPOSOMES IN A CARRIER COMPRISING A CONTINUOUS HYDROPHOBIC PHASE FOR DELIVERY OF POLYNUCLEOTIDES IN VIVO - The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject. | 2010-08-12 |
20100203117 | ANTI-ADIPOGENIC COMPOSITIONS CONTAINING PIPER BETLE AND DOLICHOS BIFLORUS - Herbal compositions are useful for inhibition, amelioration or prevention of adipogenesis mediated diseases such as obesity, lipid storage disease and hyperlipemia. The herbal compositions comprise biologically effective amounts of extracts or fractions from | 2010-08-12 |
20100203118 | COLLAPSIBLE WATER-CONTAINING CAPSULES - Collapsible water-containing capsules comprising by weight: (a) from about 40% to about 95% of a water phase the water phase comprising at least 50% water by weight of the water phase; and (b) from about 5% to about 20% of a spindle-shaped metal oxide powder which is hydrophobically surface-treated and has an average long axis particle size of from about 25 nm to about 150 nm, an average short axis particle size of from about 4 nm to about 50 nm, and an aspect ratio of greater than about 3. | 2010-08-12 |
20100203119 | PHARMACEUTICAL TREATMENT PROCESS USING CHITOSAN OR DERIVATIVE THEREOF - The present invention provides a solid composition for oral administration comprising:
| 2010-08-12 |
20100203120 | PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS - An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases [FIG. | 2010-08-12 |
20100203121 | FORMATION OF NANOMETRIC CORE-SHELL PARTICLES HAVING A METAL OXIDE SHELL - A process for preparing nanocapsules having a core-shell structure, comprising: | 2010-08-12 |
20100203122 | Delivery System for Remote Treatment of an Animal - A remote treatment delivery system comprising a substantially non-skin piercing dosage projectile containing a biologically active agent and a transdermal carrier. | 2010-08-12 |
20100203123 | METHODS FOR IMPROVING COGNITIVE FUNCTION AND DECREASING HEART RATE - The present invention is directed to methods of improving cognitive function in subjects having age related cognitive decline or mild cognitive impairment and to methods of decreasing heart rate in a subject by administering dosage forms comprising docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA). | 2010-08-12 |
20100203124 | Kappa-2 Carrageenan Composition and Products Made Therefrom - The present invention is directed to a kappa-2 carrageenan composition comprising: (i) kappa-2 carrageenan, (ii) at least 70% sodium by weight of all cations in the composition; and (iii) free salt present in an amount of 0-25% by weight of the composition; wherein the composition has a viscosity of 20 cps to 40 cps. The present invention is also directed to products made from such kappa-2 carrageenan composition, as well as to processes of manufacture and use thereof. | 2010-08-12 |
20100203125 | SYNERGISTIC ANTIBACTERIAL FORMULATION AND A METHOD OF MAKING THE SAME - An antibiotic formulation including penicillinase resistant penicillin, cefixime trihydrate, | 2010-08-12 |
20100203126 | MULTILAYERED VITAMIN COMPLEX TABLET CONTAINING UBIDECARENONE - The present invention relates to a multi-layered vitamin/mineral complex tablet having enhanced stability of ubidecarenone. The present invention is characterized in that ubidecarenone is contained in a first layer, and ingredients decreasing the stability of ubidecarenone are contained in an additional layer separated from the first layer. The method is a convenient process, and the formulation prepared by the method can maintain a high content of ubidecarenone during long-term storage, thereby providing a simultaneous intake of ubidecarenone and nutritional ingredients such as various vitamins. | 2010-08-12 |
20100203127 | LARGE DOSE RIBAVIRIN FORMULATIONS - The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin. | 2010-08-12 |
20100203128 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 2010-08-12 |
20100203129 | CONTROLLED RELEASE FORMULATIONS WITH CONTINUOUS EFFICACY - The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual. | 2010-08-12 |
20100203131 | ENTERIC COATED, SOLUBLE CREATINE AND POLYETHYLENE GLYCOL COMPOSITION FOR ENHANCED SKELETAL UPTAKE OF ORAL CREATINE - An oral creatine formulation includes soluble creatine and polyethylene glycol, coated with an enteric coating. The most preferred soluble creatine is creatine HCl. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000. | 2010-08-12 |
20100203132 | Pharmaceutical Compositions Comprising NEP-Inhibitors, Inhibitors of the Endogenous Endothelin Producing System and AT1 Receptor Antagonists - A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT | 2010-08-12 |
20100203133 | HIGH DRUG LOAD TABLET - The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula | 2010-08-12 |
20100203134 | SPHEROIDS AND MULTIPARTICULATE TABLETS COMPRISING THEM - The invention relates to a directly-compressible gastro-resistant spheroid. The spheroid comprises: (i) a core containing one or more active substances; (ii) a flexible, deformable film which directly coats the aforementioned core and which comprises an enteric polymer and a mixture of saturated and/or unsaturated polyglycosylated glycerides, the fatty acids of which include at least 8 carbon atoms; and (iii) an outer water-dispersible layer containing at least one disintegrating agent. The invention further relates to multiparticular tablets comprising said spheroids. | 2010-08-12 |
20100203135 | Skin Equivalent Culture - Methods of forming soft connective tissue compositions such as skin equivalents, compositions made by the methods and their uses. In particular, a method of forming a connective tissue equivalent, comprising the steps of: (i) incubating collagen-producing cells in or on a support matrix; (ii) inducing and/or enhancing collagen production by the collagen-producing cells to form a collagenous construct and degradation and replacement of the support matrix; (iii) freeze-drying the construct; and (iv) re-populating the freeze-dried construct with collagen-producing cells and/or epithelial cells and/or endothelial cells and/or mesenchymal cells, thereby forming a connective tissue equivalent, wherein: (a) the collagen-producing cells are substantially fibroblasts; for example human neonatal dermal fibroblasts; (b) the support matrix is a provisional support matrix in which the support matrix is a fibrin matrix, for example formed by thrombin-mediated polymerisation of fibrinogen; and (c) as a result of the collagen production by the collagen-producing cells the provisional fibrin support matrix is digested by the cells and is replaced by collagen, thereby essentially replacing the provisional fibrin matrix with a collagen matrix synthesised in situ by the cells. | 2010-08-12 |
20100203136 | METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (Hcg) VACCINE FOR LONG-ACTING ANTIBODY PROTECTION - This invention comprises a method of immunization in which human chorionic gonadotropin (hCG) vaccine antigens are incorporated into an inorganic salt/biopolymer complex using a simple manufacturing process. The resulting solid matrix is administered to human subjects in the form of microparticles. The method comprises suspending microparticles in an emulsion of a natural oil and water containing an adjuvant compound acceptable for human use and injecting a pharmaceutical dose of the suspension intramuscularly. The vaccine antigens are conjugates of peptide fragments of the beta subunit of hCG with a carrier protein, diphtheria toxoid. Vaccine antigens delivered in this formulation are effective for eliciting antibodies in recipients for the treatment of cancer or hormone-related diseases. | 2010-08-12 |
20100203137 | FORMULATION OF MENINGITIS VACCINES - A liquid Hib component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined meningitis vaccine. A lyophilised meningococcal component can also be reconstituted with an oil-in-water emulsion. | 2010-08-12 |
20100203138 | Controlled Release Composition Comprising a Recombinant Gelatin - The invention relates to the field of pharmacology. More specific, the invention relates to a controlled release composition. In one of the embodiments, the invention provides a method for preparing a controlled release composition comprising the steps of:
| 2010-08-12 |
20100203139 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising a | 2010-08-12 |
20100203140 | METHODS, COMPOSITIONS, AND KITS FOR ORGAN PROTECTION DURING SYSTEMIC ANTICANCER THERAPY - Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents. | 2010-08-12 |
20100203141 | STIMULI-RESPONSIVE LOW SOLUBILITY HYDROGEL COPOLYMERS OF N-ISOPROPYL ACRYLAMIDE AND SYNTHESIS METHOD - Preferred embodiment stimuli-responsive low solubility copolymer hydrogel compositions of the invention include polymerized N-isopropylacrylamide and water insoluble monomer or oligomer repeating units. The repeating units are arranged within the polymer backbone of the copolymer hydrogel. In a preferred fabrication method, precursors of N-isopropylacrylamide and precursors of the water insoluble monomer of oligomer are solved in a liquid solvent to form a solution in a container. An initiator is added to the solution. Gas is bubbled through the solution, and the container is sealed. The solution is stirred while heating to a polymerization temperature and polymerization is permitted to complete to form the copolymer hydrogel composition. | 2010-08-12 |
20100203142 | AMPHIPHILIC COMPOUND ASSISTED NANOPARTICLES FOR TARGETED DELIVERY - The present invention generally relates to nanoparticles with an amphiphilic component. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries. | 2010-08-12 |
20100203143 | SYSTEMS AND METHODS FOR NANOMAGNETIC ACTUATION OF MOLECULAR CELL SIGNALING - The present invention relates to signaling mechanisms that transduce magnetic inputs into physiological cellular outputs. More particularly, the present invention relates to systems and methods for non-invasively controlling cellular signaling functions and behaviors by harnessing receptor-mediated and intracellular molecular-mediated signal transduction using nanomagnetic cellular switches. | 2010-08-12 |
20100203144 | Immobilized Metallic Nanoparticles as Unique Materials for Therapeutic and Biosensor Applications - The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles. | 2010-08-12 |
20100203145 | CONTINUOUS PROCESS FOR MICROSPHERES PRODUCTION BY USING EXPANDED FLUIDS - The invention concerns a process for the continuous treatment of an emulsion and/or a micro-emulsion assisted by an “expanded liquid” for the production of micro- and/or nano-particles or micro- and/or nano-spheres containing one or more active ingredients. In particular, a liquid solvent expanded by compressed or supercritical CO | 2010-08-12 |
20100203146 | INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRITIS - The present invention provides methods of treating rheumatoid arthritis. The methods generally involve an intermittent dosing strategy for administering Atiprimod alone or in combination with a second therapeutic agent wherein the second therapeutic agent is selected from the group consisting of Methotrexate, gold compounds, antimalarials, cyclosporine A, leflunomide, azathioprine, sulfasalazine d-penicillamine, aurothioglucose, auranofin, or a TNF inhibitor. | 2010-08-12 |
20100203147 | Viruses for the Treatment of Cellular Proliferative Disorders - Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent. | 2010-08-12 |
20100203148 | Encapsulation and Controlled Release of Small Molecules for Intracellular Delivery Using Thermally Responsive Nanocapsules - In accordance with certain embodiments of the present disclosure, a method for intracellular delivery of small molecules is provided. The method includes encapsulation of small molecules in a thermally responsive nanocapsule by decreasing the temperature of the nanocapsule to increase the permeability of the nanocapsule and allowing the small molecules to be suck into or diffuse into the nanocapsule. The nanocapsule is delivered into a cell by increasing the temperature of the nanocapsule. The small molecules are released from the nanocapsule into the cell in a controllable manner by cooling and heating treatments. | 2010-08-12 |
20100203149 | Nanoparticles for Cytoplasmic Drug Delivery to Cancer Cells - The invention is a nanoparticle that contains an anticancer drug that is released in cancer cells when administered to a subject. The nanoparticles have a core including the anticancer drug and polymer chains that are soluble at the pH of the cancer cell. The core is surrounded by a layer of polymer chains that are insoluble at the pH of healthy tissue but soluble at the pH of the cancer interstitium. An outside layer is made of water-soluble polymer chains to shield the nanoparticle from RES recognition and give the nanoparticle a long circulation time in the bloodstream of the subject. The outside layer may also include folic acid moieties that bind folic acid receptors on the surface of the cancer cell. | 2010-08-12 |
20100203150 | Novel amphiphilic copolymers and fabrication method thereof - The present invention discloses a comb-like amphiphilic copolymer comprising a hydrophilic segment and a hydrophobic segment. It also discloses a novel fabrication method for synthesizing said amphiphilic copolymers. A novel initiator comprising a drug molecule, e.g. 5′-DFUR, bonded to one or two macromolecules of a hydrophobic polymer is provided. A spherical micelle with core-shell structure is formed by self-aggregation of said amphiphilic copolymer. It discloses a micelle-like nanoparticle comprising one or more said amphiphilic copolymers. The nanoparticles contain said drug molecules innately with no need to encapsulate the desired drug into the nanoparticles. The nanoparticles can serve as micellar drug carriers for delivering the drug. A nanocarrier comprising said nanoparticle and an active water-insoluble substance, e.g. SN-38, Camptothecin, encapsulated in the nanoparticle is also disclosed. The nanocarriers can serve as a means of cocktail therapy to deliver a mixture of two kinds of drugs to affected parts. | 2010-08-12 |
20100203151 | MICROSPHERES HAVING CORE/SHELL STRUCTURE - Disclosed are microspheres having a core/shell structure and a spherical shape, wherein (a) the core comprises solid-state aripiprazole, and (b) the shell coats all or most of the surface of the core, and the shell comprises a biodegradable polymer; a process for producing the microspheres; and an injectable aqueous suspension formulation containing the microspheres; and the like. | 2010-08-12 |
20100203152 | MIXED METAL COMPOUNDS USED AS ANTACIDS - There is provided use of a mixed metal compound in the manufacture of medicament for neutralising or buffering stomach acid, wherein the mixed metal compound contains at least one trivalent metal selected from iron (III) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, wherein (A) the mixed metal compound is of formula (I): M | 2010-08-12 |
20100203153 | SUSTAINED-RELEASE NANOPARTICLE COMPOSITIONS AND METHODS USING THE SAME - The present invention is a composition composed of a therapeutic agent encapsulated in a copolymer of an N-alkylacrylamide, a vinyl monomer, and a polyethylene glycol (PEG) conjugate and a method for using the same in the treatment or prevention of a disease or condition. | 2010-08-12 |
20100203154 | Elasmobranch-Repelling Compounds, Methods of Use and Devices - Elasmobranch-repelling compositions are prepared from elasmobranch carcasses. Extraction of these elasmobranch carcasses with polar solvent after a period of aerobic decay yields semiochemical repellents that induce a flight reaction in sharks when introduced into the sharks' oceanic proximity. | 2010-08-12 |
20100203155 | SEGMENTED DELIVERY SYSTEM - A covering for delivering a substance or material to a surgical site is provided. The covering, with substance provided therein, may be referred to as a delivery system. Generally, the covering may be a single or multi-compartment structure capable of at least partially retaining a substance provided therein until the covering is placed at a surgical site. Upon placement, the covering may facilitate transfer of the substance or surrounding materials. For example, the substance may be released (actively or passively) to the surgical site. The covering may participate in, control, or otherwise adjust the release of the substance. In various embodiments, the covering may be formed of a collagen material and is suitable for a variety of procedure specific uses. | 2010-08-12 |
20100203156 | XENON AS A TREATMENT FOR HEMOGLOBINOPATHY - The method disclosed herein entails treating a person, with sickle cell disease and who is suffering a pain crisis, with an effective amount of xenon, which alleviates the pain. Inhalation of xenon at subanesthetic concentrations has significant analgesic properties, which are mechanistically independent from the opioid receptor system. Inhaled xenon diminishes the propensity of sickle hemoglobin to aggregate by occupying critical internal cavities within the sickle hemoglobin molecule. Decreased hemoglobin polymerization and red blood cell sickling is beneficial during acute crisis and reduces the high incidence of sickle cell related complications after surgery. | 2010-08-12 |
20100203157 | COMBINATIONS OF PYRIMETHANIL AND SILVER COMPOUNDS - The present invention relates to combinations of pyrimethanil, or a salt thereof, and silver compounds which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of pyrimethanil, or a salt thereof, together with one or more silver salts selected from silver acetate, silver alginate, silver azide, silver citrate, silver lactate, silver nitrate, silver sulfate, silver chloride, silver thiocyanate, silver-sodium-hydrogen-zirconium phosphate, silver sulfadiazine, silver cyclohexanediacetic acid and disilver 2,5-dichloro-3,6-dihydroxy-2,5-cyclohexadiene-1,4-dione; in respective proportions to provide a synergistic biocidal effect. Other suitable silver components (II) are products that set silver free using technologies to make it gradually biologically available such as by ion exchange mechanisms such like using zirconium phosphate based ceramics as a reservoir, or silver provided in glass ceramics as reservoir or carrier, or silver provided with zeolites, silica gel or titanium dioxide as a reservoir or an inorganic derivative containing silver, incorporated into a plastic composition for the preparation of moulded, lacquered or painted products, such as an amino resin (e.g. urea-formaldehyde resin, melamine formaldehyde resin . . . ) or a thermoplastic (e.g. a polyester, polyethylene, polyacrylate, pvc . . . ), or provided as nano-silver particles typically with a particle size of 1-1000 nm. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, and the like. | 2010-08-12 |
20100203158 | ANTISEPTIC COMPOSITIONS AND USES THEREOF - Antiseptic compositions and kits containing a source of silver ions and menthol, which act in synergy such that a concentration of silver ions in the composition is substantially reduced, are disclosed. Further disclosed are uses of the antiseptic compositions as disinfectants and in the treatment of wounds. | 2010-08-12 |
20100203159 | METAL COMPONENT ABSORPTION ENHANCER IN PLANT - The invention provides a metal component absorption enhancer which enhances the absorption of at least one metal component selected from the elements belonging to the groups 2 to 12 in the third to fourth periods when a plant grows. An absorption enhancer of at least one metal component selected from the elements belonging to the groups 2 to 12 in the third to fourth periods in a plant, which comprises 5-aminolevulinic acid or a derivative thereof represented by the following general formula (1), or a salt thereof as an active ingredient: | 2010-08-12 |
20100203160 | Vitamin/Mineral Composition with DHA - Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient to supply expectant and new mothers and their children as recommended on a daily basis. This DHA may also be used to treat a variety of disorders in children and adults. The compositions advantageously include vitamins, minerals, and optionally other nutrients to provide a nutritional supplement which may be convenient to swallow and taken once a day. | 2010-08-12 |
20100203161 | STERILISATION AND CONSERVATION OF LIQUIDS - The invention relates to products, containing a solid biocide and a composite material ( | 2010-08-12 |
20100203162 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-ox- o-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid - Methods of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid are disclosed. Also provided are pharmaceutical compositions comprising (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid, and methods of treatment using such compositions. | 2010-08-12 |
20100203163 | INJECTABLE POLYMER-LIPID BLEND FOR LOCALIZED DRUG DELIVERY - An injectable polymer-lipid blend is provided as a localized drug delivery system for a pharmaceutically active agent. The blend may be prepared from a chitosan-based material, fatty acid and phospholipid. The chitosan-based material may be a water soluble chitosan derivative. The fatty acid may be a fatty acid or a fatty aldehyde, such as laurinaldehyde, having an acyl chain length of C8-C16. The rheological properties of the blend relates to the ratio of the components and to the acyl chain length of the fatty acid. The injectable system is well suited for the delayed release of pharmaceutically active agents in the treatment of cancer and other diseases requiring localized drug delivery | 2010-08-12 |
20100203164 | Therapeutic Treatment of Cancer and Dysplasia of the Cervix or Vagina Using Estrogen Antagonists - A method for treatment of cervical or vaginal cancer and their associated dysplasia, including the steps of identifying a human cervical or vaginal cancer and/or dysplasia patient, administering an effective amount of an estrogen antagonist therapy to the patient, wherein the amount is effective to reduce cancer and dysplasia symptoms, and observing a reduction of cancer and dysplasia symptoms in the patient. | 2010-08-12 |
20100203165 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS OR CONDITIONS OF THE EYE - The invention provides compositions comprising low concentrations of selective α-2 adrenergic receptor agonists in combination with potassium and/or calcium. Methods for treating eye disorders and conditions are also provided. The compositions preferably comprise brimonidine. | 2010-08-12 |
20100203166 | METHODS OF PREVENTING RESPIRATORY INFECTIONS - Methods for inhibiting the development of respiratory infections in humans are disclosed. One embodiment of the methods comprises pouring a predetermined amount of an oral rinse, capable of rendering ineffective a pathogen which has recently infected the respiratory tract, into the mouth of the human, agitating the oral rinse with air for a predetermined period in order to generate concentrated vapor of the oral rinse, stopping the agitating a plurality of times during which the head is tilted forward to allow the predetermined amount of an oral rinse to move away from the back of the mouth and throat, then exhaling before inhaling such that the concentrated vapor of the oral rinse is gently forced along with exhaled air from the throat thorough the nasopharynx and the nasal passages of the human, and then inhaling slowly to pass air over the oral rinse in the mouth such that concentrated vapor of the oral rinse is gently forced along with inhaled air through the larynx, over the vocal cords, and through the trachea to the lungs. The method is performed within about one hour after the human experiences the first minor symptom and before the onset of the first major symptom of infection of the respiratory tract. | 2010-08-12 |
20100203167 | AZEOTROPE COMPOSITIONS COMPRISING DECAFLUOROPENTANE AND HYDROGEN FLUORIDE AND USES THEREOF - Disclosed herein are azeotrope compositions comprising 1,2,3,3,3-pentafluoropropene and hydrogen fluoride. The azeotrope compositions are useful in processes to produce and in processes to purify 1,2,3,3,3-pentafluoropropene. Additionally, disclosed herein are azeotrope and near-azeotrope compositions comprising 1,1,1,2,3,4,4,5,5,5-decafluoropentane and hydrogen fluoride. | 2010-08-12 |
20100203168 | Bone microenvironment modulated seizure treatments - Novel etiology underlying certain types of seizures is presented, whereby changes in endocrine levels result in changes in osteoclast activity levels which in turn result in elevated extracellular Ca2+ levels which in turn result in systemic alterations in nerves, including increased membrane depolarization and enhanced neurotransmitter release, which in turn result in increased seizure risk in people with low seizure thresholds. Treatment methods are provided that modulate the bone microenvironment to provide an etiology based seizure treatment method based on the novel disclosures. The treatment methods include use of compounds such as calcitonin, SERMs such as raloxifene, testosterone, estrogen, calcimimetics such as cinacalcet, RANKL inhibitors such as denosumab, and bisphosphonates such as risedronate. | 2010-08-12 |
20100203169 | Composition and Method of Treating Side Effects From Antibiotic Treatment - A method of treating side effects of antibiotic treatment includes the step of internally administering an antibiotic that is capable of inducing hearing loss in a mammal. The method further includes the step of internally administering a composition to the mammal in conjunction with administration of the antibiotic. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, vitamin E, vitamin C, and a vasodilator comprising magnesium. The combination of vitamins and the vasodilator comprising magnesium, in the biologically effective amounts, provides an effective treatment for treating side effects of antibiotic treatment. | 2010-08-12 |
20100203170 | METHOD FOR FORMULATING AGROCHEMICAL ACTIVE INGREDIENTS SO AS TO REGULATE THEIR RELEASE KINETICS, PROTECT THEM FROM OUTSIDE STRESSES, AND KEEP THEIR USERS SAFE - The invention pertains to a new method for formulating any agrochemical active ingredient so as to protect the user, protect this active ingredient from outside stresses, and control its release kinetics. It relies on the use of acrylic and thickening emulsions with a pH greater than five and containing hydrophobic groups in order to trap said active ingredient. The invention also pertains to the various embodiments of the active ingredient thereby formulated: a mixture in water of that active ingredient with these thickening emotions, a dispersion of solid particles of these polymers and this active ingredient after a certification, and the solid particles obtained in a dried state after the water has been removed. Finally, the invention pertains to the use of these various formulations in order to protect and active ingredient, protect its user, and slow its release kinetics. | 2010-08-12 |
20100203171 | Therapeutic Foam - A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed. | 2010-08-12 |
20100203172 | SODIUM NITRITE-CONTAINING PHARMACEUTICAL COMPOSITIONS - Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite. | 2010-08-12 |
20100203173 | SILICA DISPERSION - Dispersion containing, in addition to water, 0.5 to 20% by weight of hydrophobic silica, 0.01 to 10% by weight of a gelling additive, or viscosity-increasing additive which, as further components, contains at least one phenol or at least one phenol derivative and/or at least one aldehyde. It is prepared by dispersing the individual components successively or together in water, in which case the individual components are deaerated before and/or during the addition or the dispersion is deaerated during the individual dispersion steps and thereafter the residual air present in the dispersion is removed by application of vacuum. The dispersion can be used as insecticide and for controlling pathogenic agents. | 2010-08-12 |
20100203174 | PET FOOD COMPOSITION FOR REGULATING BODY WEIGHT AND PREVENTING OBESITY AND RELATED DISORDERS IN PETS - The invention relates to a pet food composition for regulating body weight and preventing obesity and related disorders in pets, which comprises as an active ingredient at least one plant or plant extract having the ability to stimulate energy expenditure and/or fat burning. The invention also relates to a method for improving the health of pets, particularly by preventing obesity and metabolic disorders associated with obesity in pets. It also relates to a method for increasing energy expenditure, controlling the glucose homeostasis and improving activity or mobility of the pet. | 2010-08-12 |
20100203175 | DEGLYCATION OF AGEs - The invention relates to the use, as an active ingredient, of at least one substance that promotes the deglycation of AGEs for preparing a composition, especially for limiting the presence of AGEs in a tissue. | 2010-08-12 |
20100203176 | METHOD FOR REDUCING WEIGHT IN A SUBJECT - A method is provided for reducing weight in a subject by administering an effective amount of a composition comprising omega-3 polyunsaturated fatty acid (PUFA), at least one of L-arginine, L-ornithine, an L-arginine precursor and an L-ornithine precursor, and at least one of a nucleobase, a nucleoside and a nucleic acid. The method can also be used to treat obesity, hyperlipidemia, diabetes and/or hypertension and for improving diathesis, or treating adult disease or disposition to adult disease. | 2010-08-12 |
20100203177 | USE OF ANABOLIC AGENTS, ANTI-CATABOLIC AGENTS, ANTIOXIDANT AGENTS AND ANALGESICS FOR PROTECTION, TREATMENT AND REPAIR OF CONNECTIVE TISSUES IN HUMANS AND ANIMALS - The present invention relates to compositions for the modulation of inflammation in connective tissues in humans and animals and the modulation of markers of such inflammation, including COX-2, TNF-a, IL-1 (3, iNOS, p38, and chemokines, comprising any or all of anabolic, anti-catabolic, anti-oxidant and analgesic agents, including aminosugars, S-adenosylmethionine, arachadonic acid, GAGs, including pentosan, collagen type II, tetracyclines or tetracycline-like compounds, diacerin, super oxide dismutase, L-ergothioneine, methyl sulfanylmethane, one or more avocado/soybean unsaponifiables, and an analgesic, e.g., acetaminophen, and to methods of treating humans and animals by administration of these novel compositions to humans and animals in need thereof. | 2010-08-12 |
20100203178 | SYNERGISTIC HERBAL COMPOSITION - A present invention relates to the synergistic herbal ophthalmic composition, which delays the onset and progression of cataract. The product is suitable for prophylactic treatment of cataract of different degree. The herbs are cleaned coarsely ground, weighed as per formula and extracted using different solvents preferably water, filtered or centrifuged to collect the clear filtrate and formulated in the form of sterile ophthalmic drops, gel, ointment, cream etc for said therapeutic purpose. | 2010-08-12 |
20100203179 | Bioactive Water Fraction from Gomphostema Niveum - The present invention relates to a novel bioactive water fraction obtained from the leaves of an herb named | 2010-08-12 |
20100203180 | Antimicrobial protein derived from podoviriedae bacteriophage specific to staphylococcus aureus - The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to | 2010-08-12 |
20100203181 | EXTRUSION APPARATUS FOR MAKING MULTILAYER ARTICLES - In certain aspects of the invention, an extrusion apparatus for making a multilayer article includes multiple discs, each of which has at least one passageway configured to permit fluid flow therethrough in a flow direction. At least one of the discs includes a cone shaped portion extending substantially parallel to the flow direction. | 2010-08-12 |
20100203182 | EXTRUSION GRANULATOR FOR GRANULATION OF PLASTIC STRANDS - The invention concerns an extrusion granulator for the granulation of plastic strands gripped by a pair of feed rollers and directed over a slideway in the direction of a cutting rotor with an opposing blade. A guided air stream directed onto the slideway, and deflected perpendicularly towards the cutting rotor by said slideway, impinges on the strands carried on the slideway with such a speed that the strands are held in a parallel orientation by the air stream. | 2010-08-12 |
20100203183 | ROLLER TYPE STAMPER - A roller type stamper includes a roller; a stamper film including a first surface having a pattern, and a second surface opposite the first surface and connected to an outer circumferential surface of the roller at least one connecting portion; and a planarizing portion for filling a groove approximate the at least one connecting portion. | 2010-08-12 |
20100203184 | Extruder Stabilizer Assembly - A stabilizer assembly for use in an extruder having a screw rotating in a barrel is provided. The assembly comprises a plurality of rods that are secured to an interior of the barrel at one end. Each of the rods has an end that extends radially inwardly toward the center of the barrel. On the discharge end of the screw, there is a bearing member that is in contact with each of the opposite ends of the rods. The rods support the discharge end of the screw and stabilize its rotation in the barrel. | 2010-08-12 |
20100203185 | DEVICE FOR BLOW MOLDING CONTAINERS - The invention relates to a device for blow molding containers. The temperature of parisons, which are made of a thermoplastic material, is adjusted and the parisons are then molded in a blow mold under the effect of a pressurized medium to give containers. The blow mold which is composed of at least two blow mold segments is held in place by mold supports of a blow molding station ( | 2010-08-12 |
20100203186 | Mold assembly - A mold assembly has two mold half shells each having an outer and inner wall for defining the shape of a container to be formed. Two mold half carriers each have an inner wall overlaying and spaced from a corresponding mold shell outer wall for supporting the shells in the assembly. At least one insulating pad is sandwiched between the inner wall and the corresponding outer wall and is secured to one of the inner wall and the outer wall. The pad supports the outer wall in non-contacting and buffering relation relative the carrier inner wall. Each pad may be secured in a recessed seat in the respective wall. Pads may be secured in recessed seats having a depth less than the thickness of the pad. Pads absorb mold operational forces to reduce wear, reduce conduction from shell to carrier and facilitate the use of different-sized shells with one carrier. | 2010-08-12 |
20100203187 | APPARATUS FOR PRODUCING PLASTIC CONTAINERS - An apparatus for moulding plastic preforms into plastic containers may include at least one blow mould and a plurality of closure elements cooperating with one another in order to transfer the blow mould between an open condition and a closed condition, in which the blow mould forms a cavity, within which the plastic preforms may be expanded into plastic containers. The closure elements include at least one first mould section and one second mould section. The first mould section and the second mould section may be moved between the closed position and the open position in relation to one another. In a closed condition, the first and second mould sections are locked together. The closure elements may further include a bottom section which may be moved relative to the first and second mould sections in order to close the cavity in one direction. According to various aspects, the bottom section initiates the closing of the mould sections and/or the locking of the mould sections in a closed condition of the blow mould. | 2010-08-12 |
20100203188 | INJECTION MOLDING MACHINE - According to one embodiment, an injection molding machine includes a first die and a second die, a driving mechanism configured to move the second die between the first position and the second position, a holder configured to hold a film for in-mold formation, the film including metallic sheets used for covering the surface of the molded product, and an electric discharge mechanism. The electrical discharge mechanism is moved to a contact position with movement of the second die from the first position to the second position, used as a driving source. The electrical discharge mechanism is moved to a retracted position with movement of the second die from the second position to the first position, used as a driving source. | 2010-08-12 |
20100203189 | Mycellated grain and other myceliated agricultural materials to be used as animal food supplement - Animal feedstuff having beneficial properties is obtained by adding to a substrate one or more fungal species of the kind that excretes substances into said substrate during its growth which are beneficial to the health, growth or weight gain of an animal, or animals to which the feedstuff is intended and allowing the fungus to grow and/or ferment on the substrate. Suitable substrates are cereal grains, residue of cereal grains, agricultural primary products, agricultural waste products, and other cellulosic materials or a combination of one or more of the same. Suitable fungus species include | 2010-08-12 |
20100203190 | COATED CONFECTIONERY PRODUCTS - Coated confectionery products and methods of making the coated confectionery products are provided. In a general embodiment, the present disclosure provides a confectionery product comprising a confectionery center, and a coating comprising erythritol and an anti-crystallizing agent surrounding the confectionery center. For example, the weight ratio of the erythritol to the anti-crystallizing agent in the coating can be between about 20:80 and about 80:20. | 2010-08-12 |
20100203191 | LIQUID-FILLED CHEWING GUM COMPOSITION - Some embodiments provide a chewing or bubble gum composition which includes a liquid fill composition and a gum region which includes a gum base surrounding the liquid fill which may include a modified release component, wherein the gum region includes a polyol composition including at least one polyol and having a water solubility of less than 72% by weight at 25° C. The composition may also include a coating region which surrounds the gum region. | 2010-08-12 |
20100203192 | CHEW TOY WITH FABRIC OR FABRIC LAYERING - The present disclosure relates to chew toys comprising a fabric and a polymeric material. The fabric and polymeric material may be present as one or more layers. The chew toys may specifically include a fabric having an outer or exposed surface which may include written/printed indicia. The fabric may be capable of stretching with the polymeric layer and the fabric layer may have an inner surface substantially engaged to the polymeric material. Such engagement may therefore avoid delamination and present a relatively smooth surface without disruptions. Such composite may therefore provide durability and resistance to an animal chewing action. | 2010-08-12 |
20100203193 | Freezer to Retarder to Oven Dough - A frozen dough comprising flour, a high yeast level comprising one or more yeast with activity covering temperature range of 33-140° F., emulsifiers, dough conditioners, stabilizers, sugar, lipid source and optionally supplemental gluten such that the frozen dough does not require a conventional proofing (proofer) step prior to freezing or prior to baking. When the frozen dough is thawed in a retarder at 33-42° F. for at least 12 hours, or at an elevated temperature of between 43-85° F. for at least 1 hour, and then baked, the baked products have good appearance, taste and texture, and a specific volume of at least 4 cc/gram. | 2010-08-12 |
20100203194 | FEMENTED FOOD PRODUCT - The present invention relates to a fermented food product, which comprises defatted flax-seed as main raw material. Suspension of defatted crushed flaxseed or crushed and milled flaxseed, optionally supplemented with other cereals or plant seeds or flaxseed fractions, is fermented by a starter culture which comprises probiotic bacteria, and seasoned and stabilized, whereby a spoonable or thinkable fermented snack product is obtained. | 2010-08-12 |
20100203195 | Process for Separating High Purity Germ and Bran from Corn - A semi-wet process for refining corn to make a feedstock for ethanol production. Corn is tempered at a moisture content from about 20-25% by weight for a very short time followed by grinding. The ground corn is not dried and cooled before further processing. It is graded and then ground and sifted to make an endosperm fraction and a high purity fraction of germ and bran. The fraction of germ and bran can be separated in a one or two stage dry separation process or in a wet separation process. In the wet separation process, the fraction of germ and bran is enzymatically steeped, dewatered and then separated in hydrocyclones to produce a germ fraction and a bran fraction. | 2010-08-12 |
20100203196 | MAIZE HAVING IMPROVED DIGESTIBILITY - The invention relates to maize having a reduced level of CAD2 activity due to the presence of the Δ314 allele, and to the use thereof for sillage. | 2010-08-12 |
20100203197 | Sports Drink Acid Blend To Reduce Or Eliminate Aftertaste - An improved sports beverage containing an acidulant system that results in a sports beverage with reduced total aftertaste and an increase in the pleasantness of the aftertaste as well as significantly higher gulpability compared to conventional sports beverages. The acidulant system is composed of citric and phosphoric acid in specific relative amounts. | 2010-08-12 |
20100203198 | CAPSULE AND METHOD FOR PREPARING A FOOD LIQUID BY CENTRIFUGATION - A single-use capsule for preparing a food liquid from a food substance contained in the capsule by introducing water in the capsule and passing water through the substance using the centrifugal forces for producing the food liquid which is centrifuged peripherally in the capsule relatively to a central axis of the capsule corresponding to an axis of rotation during the centrifugation. The capsule has upper and bottom walls, a widening side wall connecting to the upper and lower walls and an enclosure containing a predetermined amount of a food substance. The upper wall has a peripheral outlet region which is perforable and dedicated for providing outlets for the release of the liquid. | 2010-08-12 |
20100203199 | Packaged Salad - There is disclosed a packaged salad. The packaged salad includes an undressed salad comprising a plurality of solid food items, and a package containing the salad. The package has a smaller distribution mode and a larger, expanded consumption mode. One or more air vents allow air to enter the package to prevent negative air pressure from impeding a user from expanding the package from distribution mode to consumption mode. Processes for using the package are also disclosed. | 2010-08-12 |
20100203200 | METHODS FOR PRESERVING FRESH PRODUCE - The present invention pertains to methods of preserving fresh produce with a produce preservative which extends the shelf life of fresh produce, particularly cut fresh produce. The produce preservative preserves the texture, flavor, appearance, crispness, and color of the fresh produce, particularly the exposed surface of the fresh produce. The method comprises the following steps: providing a solution of produce preservative comprising: water, magnesium ions or zinc ions or tin ions; and ascorbate ions, or erythorbate ions; wherein the magnesium ion or zinc ions or tin ions and ascorbate ions are present in a mole ratio of preferably from 0.2:1 to 8:1, more preferably from 0.75:1 to 8:1, more preferably from 1:1 to 4:1, most preferably 1.5:1 to 3:1, applying said produce preservative to the produce; applying said produce preservative to the produce. | 2010-08-12 |
20100203201 | FORMULATION AND PROCESS TO PREPARE A PREMIUM FORMULATED FRIED EGG - The present invention relates to the formulation and process for preparation of a fried egg product which may be frozen for future heating within a microwave or other oven for consumption by an individual. Various ingredients are added and mixed to each of the liquid egg white and liquid yolk portions. The liquid egg white portion is preheated and then deposited within a mold for slow cooking under controlled temperature and humidity conditions. The liquid yolk portion is preheated and then is added to the mold for placement on the egg white portion. Following a short period of cooking the mold containing the formulated fried eggs is transported to a freezer unit for freezing, packaging, and storage. At a future time the frozen formulated fried egg product may be retrieved for thawing and cooking for consumption by an individual. | 2010-08-12 |
20100203202 | NATURAL STABILISER SYSTEM FOR FROZEN DESSERT - The present invention relates to stabiliser systems which may be used in the manufacture of frozen dessert which comprise native rice starch, egg yolk as a natural emulsifier and fibres from vegetables, fruits or mixtures thereof. It also relates to a method for manufacturing a frozen confectionery using a stabiliser system that contains only natural ingredients. The invention, in another aspect, also concerns the frozen confectionery products thus produced. | 2010-08-12 |
20100203203 | Preparation of Soy Protein Product Using Water Extraction ("S803") - A soy protein product which is completely soluble and is capable of providing transparent and heat stable solutions at low and neutral pH values is produced by extracting a soy protein source material with water at low pH, subjecting the resulting aqueous soy protein solution to ultrafiltration and optional diafiltration to provide a concentrated and optionally diafiltered soy protein solution, which may be dried to provide the soy protein product. The soy protein product may be used for protein fortification of, in particular, soft drinks and sports drinks, without precipitation of protein. | 2010-08-12 |
20100203204 | Production of Soy Protein Product Using Calcium Chloride Extraction ("S7300/S7200") - A soy protein product having a protein content of at least about 60 wt % (N×6.25) d.b., preferably a soy protein isolate having a protein content of at least about 90 wt % (N×6.25) d.b., is prepared from a soy protein source material by extraction of the soy protein source material with an aqueous calcium salt solution, preferably calcium chloride solution, to cause solubilization of soy protein from the protein source and to form an aqueous soy protein solution, separating the aqueous soy protein solution from residual soy protein source, concentrating the aqueous soy protein solution while maintaining the ionic strength substantially constant by using a selective membrane technique, optionally diafiltering the concentrated soy protein solution, diluting the concentrated and optionally diafiltered with water to cause the formation of a precipitate, separating the precipitate from the diluting water (supernatant), and drying the separated soy protein solution to provide the soy protein product. The supernatant may be processed to form soy protein products having a protein content of at least about 60 wt % (N×6.25) d.b., preferably a soy protein isolate having a protein content of at least about 90 wt % (N×6.25) d.b. | 2010-08-12 |